MGL-3196

Drug identity checked against registry records

Also recorded as Resmetirom

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisNCT03900429MDGLPhase 3Active not recruiting2028-01Estimated
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)NCT02912260MDGLPhase 2Completed2017-10-25Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.